Merus Labs International (NASDAQ:MSLI; TSX:MSL) has appointed two key additions to its executive leadership team, effective July 1.
Dr. Michael Bumby was named CFO, succeeding Andrew Patient, who has decided to leave the company to pursue other opportunities. Mr. Patient will remain with Merus Labs for a period of time to ensure a smooth transition.
Dr. Bumby was most recently the CFO of Acerus Pharmaceuticals. He had a 14-year career at Eli Lilly, including corporate finance & investment banking at Lilly’s global headquarters in Indianapolis and leading international business development activities for early-and late-stage assets. He was also regional CFO for Lilly’s Czech and Slovak subsidiaries in Prague.
Merus also appointed Frank Fokkinga as VP, global regulatory affairs, quality and compliance. Based in Zurich, Mr. Fokkinga has over 30 years of pharmaceutical experience in regulatory affairs, global market research, business development and market access.
“Their enthusiasm, entrepreneurial spirit and expertise is expected to accelerate the execution of our growth strategy,” CEO, Barry Fishman, said in a statement, referring to Dr. Bumby and Mr. Fokkinga.